Autres langues Inozyme Pharma, Inc.

Actions

INZY

US45790W1080

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 08/05/2024			Varia. 5j.	Varia. 1 janv.
4,64 ^USD	+0,87%		+5,22%	+8,92%

07/05	Inozyme Pharma, Inc. déclare ses résultats pour le premier trimestre clos le 31 mars 2024	CI
08/04	Transcript : Inozyme Pharma, Inc. - Special Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference	08/05
Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights	07/05
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	06/05
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency	08/04
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	08/04
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/04
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024	26/03
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency	26/03
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights	12/03
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference	26/02
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/02
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/12
Inozyme Pharma to Participate in Upcoming Investor Conferences	09/11
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights	07/11
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Inozyme Pharma, Inc.

Actions

INZY

US45790W1080

Autres langues

Filtres